CN104490819A - Loratadine composition chewable tablets and preparation method thereof - Google Patents
Loratadine composition chewable tablets and preparation method thereof Download PDFInfo
- Publication number
- CN104490819A CN104490819A CN201410735868.6A CN201410735868A CN104490819A CN 104490819 A CN104490819 A CN 104490819A CN 201410735868 A CN201410735868 A CN 201410735868A CN 104490819 A CN104490819 A CN 104490819A
- Authority
- CN
- China
- Prior art keywords
- loratadine
- medicinal liquid
- drug
- chewable tablet
- containing dish
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention provides loratadine composition chewable tablets and a preparation method thereof, and relates to the technical field of medicine and medicine production. The loratadine composition chewable tablets comprise loratadine, starch and sucrose; the tablets overcome the shortcomings of common chewable tablets, and the types and amount of accessories in the loratadine chewable tablets are reduced; and the medicine preparation has good performance, high bioavailability and good stability, is highly accepted by patients, avoids gritty feel and has an important value in clinical application.
Description
Technical field
The present invention relates to medicine and medical production technical field, be specifically related to a kind of loratadine compositions chewable tablet and preparation method thereof.
Background technology
Tablet quality is stable, taking convenience, is basic, the most the most frequently used a kind of dosage form.But for the patient of child, old man and dysphagia, conventional tablet often takes difficulty, and Long-term taking medicine even can make it produce psychological phenomenon of refusing to take medicine, and chewable tablet then can remedy such and insufficient.Chewable tablet is the tablet under a class can chew posterior phraynx in oral cavity, and size is general identical with conventional tablet, can make difform Special-shaped sheet as required.Tablet is convenient to swallow after chewing, and coat tablets is long-pending to be increased, and can promote medicine dissolving in vivo, absorption.For the medicine of difficult disintegrate, make chewable tablet and can accelerate its disintegrate, improve drug effect.Chewable tablet taking convenience, even if also can medication on time under the condition of hydropenia, be specially adapted to the patient that children's, old man, dysphagia or gastrointestinal function are poor, can reduces medicine and bear gastrointestinal.Therefore, chewable tablet application is extensively got up gradually.
Loratadine is that the amphion feature in second filial generation antihistamine drug molecular structure makes it without obvious central inhibitory action, and clinical being mainly used in prevents and treats the diseases such as allergic rhinitis, chronic idiopathic urticaria, allergic asthma and atopic dermatitis.Its chemical structural formula formula is as follows:
The pharmaceutical preparation of the loratadine gone on the market have conventional tablet, granule, syrup, effervescent tablet, chewable tablet, capsule, dispersible tablet, oral cavity disintegration tablet etc., wherein loratadine chewable tablet supplementary product kind and quantity more, generally to use filler, lubricant, disintegrating agent, adhesive, correctives etc., and at least will use 4 kinds of adjuvants.Increasing research shows that impurity in the incompatibility of the toxic and side effects of adjuvant itself, adjuvant and principal agent, adjuvant etc. all can have an impact to the safety of medicine,
Therefore, select suitable adjuvant and technique, reduce supplementary product kind and the consumption of loratadine chewable tablet, improve bioavailability and the stability of loratadine chewable tablet, for ensureing that the safety of clinical application has positive effect.
Starch is polymerized by glucose molecule, it is the basic adjuvant of oral solid formulation, be usually used in chewable tablet, making adhesive, diluent and disintegrating agent, and starch all extracts from the natural materials such as Semen Maydis, Maninot esculenta crantz., safe and reliable, cheap and easy to get, but being used alone starch has no report as adjuvant for the production of chewable tablet.
Summary of the invention
Technical problem to be solved by this invention is the defect overcoming prior art, and propose a kind of loratadine compositions chewable tablet and preparation method thereof further, said preparation adjuvant is few, good stability, and bioavailability is high.
Technical problem to be solved by this invention realizes by the following technical solutions:
A kind of loratadine compositions chewable tablet, comprise loratadine, starch, sucrose, this tablet overcomes the shortcoming of above-mentioned common chewable tablet, decrease supplementary product kind and consumption in loratadine chewable tablet, this pharmaceutical preparation function admirable, bioavailability is high, have good stability, patient acceptance is high, without sand type, has important clinical value.
A kind of loratadine compositions chewable tablet, is prepared from by following raw material:
A preparation method for loratadine compositions chewable tablet, comprises step as follows:
A, take the starch of component amount, add a certain amount of purified water and stir, by pH adjusting agent, the pH value of solution is controlled between 4 ~ 9, be then heated to 72 DEG C, be incubated 120 minutes, make the gelatinizing corn starch solution of 5 ~ 15% (W/V);
B, measure purified water 45ml, boil, add 85g sucrose, stir, after dissolving, continue to be heated to 100 DEG C, filter with purified cotton, the appropriate hot distilled water of filter is cleaned, and washing liquid and filtrate merge, and let cool, add appropriate distilled water, make full dose become 100mL, stir evenly, obtain B solution;
The solution that C, the medicinal liquid and the step B that steps A are obtained obtain mixes, and fully stirs 30 minutes, after medicinal liquid be down to room temperature obtain gelatinizing Semen Maydis-sucrose system medicinal liquid;
D, take loratadine 10 grams, add 1L gelatinizing Semen Maydis-sucrose system medicinal liquid, stir 25 ~ 35 minutes;
E, the medicinal liquid sampling and measuring loratadine content obtained step D, control with sodium hydroxide or hydrochloric acid between 5.0 ~ 7.0 by pH value;
After loratadine content measured by F, medicinal liquid, be sub-packed in drug-containing dish by loading amount by medicinal liquid, each drug-containing dish fills about 1.0ml, then utilizes drug-containing dish lid malcompression state to cover drug-containing dish, and drug-containing dish is the cylindric medicine carrying packaging that plastics or other materials are made;
G, the drug-containing dish that medicinal liquid is housed is put into freeze drying box, be cooled to subzero 45 DEG C, keep 2 hours, evacuation, then 0 DEG C is warming up to gradually, keep 2 hours, then be cooled to subzero 45 DEG C, keep 2 hours, be warming up to 0 DEG C gradually again, keep 2 ~ 4 hours, then be warming up to 28 ~ 32 DEG C of dryings 4 ~ 6 hours gradually, whole process vacuum remains on below 10 handkerchiefs; Finally the drug-containing dish lid of powder charge is covered tightly, and load aluminium foil bag and carry out sealing and obtain loratadine compositions chewable tablet.
The preparation method of a kind of loratadine compositions chewable tablet of the present invention, in described steps A, pH adjusting agent is sodium hydroxide or hydrochloric acid, preferably controls 6.5 by the pH value of solution; Mixing time preferably 30 minutes in step C; In step D, pH value preferably controls 6.0, is preferably warming up to 0 DEG C gradually again in step F, keeps 3 hours, then is warming up to 30 DEG C of dryings 5 hours gradually; Described starch selects corn starch.
Beneficial effect of the present invention is:
The preparation method of a kind of loratadine compositions chewable tablet of the present invention, it adopts unique processing step, carries out special process process, can improve the bonding of starch in chewable tablet, disintegration to common corn starch, improves the molding of chewable tablet.And dosage of sucrose is 8.5% (W/V) in loratadine compositions chewable tablet, it is the hardness reinforcer of this tablet, and plays flavored action.Loratadine compositions chewable tablet only needs starch and sucrose two kinds of adjuvants, reduces the kind of required adjuvant; Because the technique of two liters falls in freeze-dry process employing two, twice cooling, twice intensification can make chewable tablet mouldability better, and improve stability and the dissolution of product, improve quality and the bioavailability of product.Therefore the preparation method of a kind of loratadine compositions chewable tablet provided by the invention has easy to operate, and prescription is simple, and technique is unique, the feature that product stability, safety are high.
Accompanying drawing explanation
Fig. 1 is the dissolution correlation curve figure of loratadine in experiment.
Detailed description of the invention
The technological means realized to make the present invention, creation characteristic, reaching object and effect is easy to understand, below in conjunction with specific embodiment, set forth the present invention further, but following embodiment being only the preferred embodiments of the present invention, and not all.Based on the embodiment in embodiment, those skilled in the art under the prerequisite not making creative work obtain other embodiment, all belong to the protection domain of this patent.
Loratadine content is for 10mg/ sheet.
Embodiment 1
Prescription: 1000 amounts
A, take the corn starch of 100g, the purified water adding 900ml stirs, and controls 6.5, is then heated to 72 DEG C, keep 120 minutes, make the gelatinizing corn starch solution of about 10% (W/V) by pH adjusting agent by the pH value of solution.
B, measure purified water 45ml, boil, add 85g sucrose, stir, after dissolving, continue to be heated to 100 DEG C, filter with purified cotton, the appropriate hot distilled water of filter is cleaned, and washing liquid and filtrate merge, and let cool, add appropriate distilled water, make full dose become 100mL, stir evenly, obtain B solution.
The solution that C, the medicinal liquid and the step B that steps A are obtained obtain mixes, and fully stirs 30 minutes, after medicinal liquid be down to room temperature obtain gelatinizing Semen Maydis-sucrose system medicinal liquid.
D, take loratadine 10g (by 1000 calculations), add 1L gelatinizing Semen Maydis-sucrose system medicinal liquid, stir 30 minutes.
E, the medicinal liquid sampling and measuring loratadine content obtained step D, control pH value 6.0 with sodium hydroxide or hydrochloric acid.
After loratadine content measured by F, medicinal liquid, be sub-packed in drug-containing dish by loading amount by medicinal liquid, each drug-containing dish fills about 1.0ml, then utilizes drug-containing dish lid malcompression state to cover drug-containing dish, and drug-containing dish is the cylindric medicine carrying packaging that plastics or other materials are made.
G, the drug-containing dish that medicinal liquid is housed is put into freeze drying box, be cooled to subzero 45 DEG C, keep 2 hours, evacuation, then 0 DEG C is warming up to gradually, keep 2 hours, be cooled to subzero 45 DEG C, keep 2 hours, be warming up to 0 DEG C gradually again, keep 3 hours, then be warming up to 30 DEG C of dryings 5 hours gradually, whole process vacuum remains on below 10 handkerchiefs.Finally the drug-containing dish lid of powder charge is covered tightly, and load aluminium foil bag and carry out sealing and obtain a kind of loratadine compositions chewable tablet.
Embodiment 2
Prescription: 1000 amounts
A, take the corn starch of 115g, the purified water adding 900ml stirs, and controls 6.5, is then heated to 72 DEG C, keep 120 minutes, make the gelatinizing corn starch solution of about 5 ~ 15% (W/V) by pH adjusting agent by the pH value of solution.
B, measure purified water 45ml, boil, add 85g sucrose, stir, after dissolving, continue to be heated to 100 DEG C, filter with purified cotton, the appropriate hot distilled water of filter is cleaned, and washing liquid and filtrate merge, and let cool, add appropriate distilled water, make full dose become 100mL, stir evenly, obtain B solution.
The solution that C, the medicinal liquid and the step B that steps A are obtained obtain mixes, and fully stirs 30 minutes, after medicinal liquid be down to room temperature obtain gelatinizing Semen Maydis-sucrose system medicinal liquid.
D, take loratadine 10g (by 1000 calculations), add 1L gelatinizing Semen Maydis-sucrose system medicinal liquid, stir 30 minutes.
E, the medicinal liquid sampling and measuring loratadine content obtained step D, control pH value 6.0 with sodium hydroxide or hydrochloric acid.
After loratadine content measured by F, medicinal liquid, be sub-packed in drug-containing dish by loading amount by medicinal liquid, each drug-containing dish fills about 1.0ml, then utilizes drug-containing dish lid malcompression state to cover drug-containing dish, and drug-containing dish is the cylindric medicine carrying packaging that plastics or other materials are made.
G, the drug-containing dish that medicinal liquid is housed is put into freeze drying box, be cooled to subzero 45 DEG C, keep 2 hours, evacuation, then 0 DEG C is warming up to gradually, keep 2 hours, be cooled to subzero 45 DEG C, keep 2 hours, be warming up to 0 DEG C gradually again, keep 3 hours, then be warming up to 30 DEG C of dryings 5 hours gradually, whole process vacuum remains on below 10 handkerchiefs.Finally the drug-containing dish lid of powder charge is covered tightly, and load aluminium foil bag and carry out sealing and obtain a kind of loratadine compositions chewable tablet.
Embodiment 3
Prescription: 1000 amounts
A, take the corn starch of 85g, the purified water adding 900ml stirs, and controls 6.5, is then heated to 72 DEG C, keep 120 minutes, make the gelatinizing corn starch solution of about 5 ~ 15% (W/V) by pH adjusting agent by the pH value of solution.
B, measure purified water 45ml, boil, add 85g sucrose, stir, after dissolving, continue to be heated to 100 DEG C, filter with purified cotton, the appropriate hot distilled water of filter is cleaned, and washing liquid and filtrate merge, and let cool, add appropriate distilled water, make full dose become 100mL, stir evenly, obtain B solution.
The solution that C, the medicinal liquid and the step B that steps A are obtained obtain mixes, and fully stirs 30 minutes, after medicinal liquid be down to room temperature obtain gelatinizing Semen Maydis-sucrose system medicinal liquid.
D, take loratadine 10g (by 1000 calculations), add 1L gelatinizing Semen Maydis-sucrose system medicinal liquid, stir 30 minutes.
E, the medicinal liquid sampling and measuring loratadine content obtained step D, control pH value 6.0 with sodium hydroxide or hydrochloric acid.
After loratadine content measured by F, medicinal liquid, be sub-packed in drug-containing dish by loading amount by medicinal liquid, each drug-containing dish fills about 1.0ml, then utilizes drug-containing dish lid malcompression state to cover drug-containing dish, and drug-containing dish is the cylindric medicine carrying packaging that plastics or other materials are made.
G, the drug-containing dish that medicinal liquid is housed is put into freeze drying box, be cooled to subzero 45 DEG C, keep 2 hours, evacuation, then 0 DEG C is warming up to gradually, keep 2 hours, be cooled to subzero 45 DEG C, keep 2 hours, be warming up to 0 DEG C gradually again, keep 3 hours, then be warming up to 30 DEG C of dryings 5 hours gradually, whole process vacuum remains on below 10 handkerchiefs.Finally the drug-containing dish lid of powder charge is covered tightly, and load aluminium foil bag and carry out sealing and obtain a kind of loratadine compositions chewable tablet.
Experimental data
The loratadine compositions chewable tablet that above-described embodiment is obtained carries out following quality research test:
1, hardness, friability, mouthfeel contrast test
The loratadine compositions chewable tablet prepared according to above-described embodiment and commercially available loratadine chewable tablet (commercially available) detect friability and hardness by " in " pharmacopeia " version two annex X G inspection techniques in 2010, contrast, the results are shown in following table:
| Sample | Hardness/N | Friability | Mouthfeel |
| Embodiment 1 | 61 | <1％ | Without grains of sand sense, crisp |
| Embodiment 2 | 63 | <1％ | Without grains of sand sense, crisp |
| Embodiment 3 | 61 | <1％ | Without grains of sand sense, crisp |
| Ordinary tablet (commercially available) | 72 | <1％ | There is grains of sand sense, more firmly |
Experimental data shows, the more commercially available loratadine chewable tablet of loratadine compositions chewable tablet on friability and hardness without significant difference, meet " Chinese Pharmacopoeia " version in 2010 to the requirement of chewable tablet, and mouthfeel is greatly improved, make it the demand more meeting patient.
2, dissolution contrast test
(No. 1 to No. 3 is embodiment 1 chewable tablet to get loratadine chewable tablet (commercially available) and loratadine compositions chewable tablet respectively, No. 4 to No. 6 is embodiment 2 chewable tablet, No. 7 to No. 9 is embodiment 3 chewable tablet) each 9, respectively according to dissolution method (" Chinese Pharmacopoeia " version in 2010 two annex X C second methods), with acetate buffer pH 6.0 solution 900ml for dissolution medium, rotating speed is 100r/min, operates in accordance with the law.
Sample respectively at 5min, 10min, 15min, 25min, 40min, 60min, get dissolution fluid appropriate, filter, get subsequent filtrate, according to " Chinese Pharmacopoeia " version in 2010 two annex IV A ultraviolet spectrophotometrys, under 260nm wavelength, measure its absorbance; Another precision takes loratadine reference substance and is about 10mg, puts in 25mL measuring bottle, and add stripping medium dissolves and be diluted to scale, shaking up, precision measures 2mL, puts in 100mL measuring bottle, adds stripping medium to scale, shakes up, be measured in the same method, calculate the stripping quantity of every sheet.Calculate every sheet stripping quantity, investigate stripping curve, result is as follows.
Loratadine compositions chewable tablet (No. 1 to No. 3 is embodiment 1, and No. 4 to No. 6 is embodiment 2, and No. 7 to No. 9 is embodiment 3)
Loratadine chewable tablet (commercially available)
Respectively with catch cropping Dissolution profiles during average dissolution pair, as Fig. 1.
As stated above to the loratadine compositions chewable tablet comparative determination of loratadine compositions chewable tablet of the present invention and commercial reference preparation, the dissolution of loratadine compositions chewable tablet when 15min (91.3%) of the present invention is suitable with loratadine chewable tablet (commercially available) dissolution when 60min (87.7%), and the dissolution of loratadine compositions chewable tablet when 60min (94.8%) of the present invention comparatively loratadine chewable tablet (commercially available) dissolution when 60min (87.7%) is higher, comparatively loratadine chewable tablet (commercially available) dissolution time is shorter to show loratadine compositions chewable tablet of the present invention, dissolution is higher, further show that loratadine compositions chewable tablet bioavailability of the present invention is better than loratadine chewable tablet (commercially available).
2, stability study
Sample source: self-control
Sample lot number: 20130801 (embodiments 1), 20130802 (embodiments 2), 20130803 (embodiments 3),
Investigation project: character, content, related substance, hardness, dissolution
Investigation method: according to " Chinese Pharmacopoeia " version in 2010 two annex XIX C crude drug and pharmaceutical preparation stability test guideline, investigate the accelerated stability (January, February, March, June) of this product and long-time stability (March, June, JIUYUE, December), result of the test is as following table:
As can be seen from the above table, in acceleration 6 months, all there is not significant change in long-term 12 months, show that this product has good stability in loratadine compositions chewable tablet indices of the present invention.
More than show and describe ultimate principle of the present invention, principal character and advantage of the present invention.The technical staff of the industry should understand; the present invention is not restricted to the described embodiments; what describe in above-described embodiment and description is only preference of the present invention; be not used for limiting the present invention; without departing from the spirit and scope of the present invention; the present invention also has various changes and modifications, and these changes and improvements all fall in the claimed scope of the invention.Application claims protection domain is defined by appending claims and equivalent thereof.
Claims (2)
1. a loratadine compositions chewable tablet, is characterized in that, is prepared from by following raw material:
2. a preparation method for loratadine compositions chewable tablet according to claim 1, is characterized in that, comprise step as follows:
A, take the starch of component amount, add a certain amount of purified water and stir, by pH adjusting agent, the pH value of solution is controlled between 4 ~ 9, be then heated to 72 DEG C, be incubated 120 minutes, make the gelatinizing corn starch solution of 5 ~ 15% (W/V);
B, measure purified water 45ml, boil, add 85g sucrose, stir, after dissolving, continue to be heated to 100 DEG C, filter with purified cotton, the appropriate hot distilled water of filter is cleaned, and washing liquid and filtrate merge, and let cool, add appropriate distilled water, make full dose become 100m L, stir evenly, obtain B solution;
The solution that C, the medicinal liquid and the step B that steps A are obtained obtain mixes, and fully stirs 30 minutes, after medicinal liquid be down to room temperature obtain gelatinizing Semen Maydis-sucrose system medicinal liquid;
D, take loratadine 10 grams, add 1L gelatinizing Semen Maydis-sucrose system medicinal liquid, stir 25 ~ 35 minutes;
E, the medicinal liquid sampling and measuring loratadine content obtained step D, control with sodium hydroxide or hydrochloric acid between 5.0 ~ 7.0 by pH value;
After loratadine content measured by F, medicinal liquid, be sub-packed in drug-containing dish by loading amount by medicinal liquid, each drug-containing dish fills about 1.0ml, then utilizes drug-containing dish lid malcompression state to cover drug-containing dish, and drug-containing dish is the cylindric medicine carrying packaging that plastics or other materials are made;
G, the drug-containing dish that medicinal liquid is housed is put into freeze drying box, be cooled to subzero 45 DEG C, keep 2 hours, evacuation, then 0 DEG C is warming up to gradually, keep 2 hours, then be cooled to subzero 45 DEG C, keep 2 hours, be warming up to 0 DEG C gradually again, keep 2 ~ 4 hours, then be warming up to 28 ~ 32 DEG C of dryings 4 ~ 6 hours gradually, whole process vacuum remains on below 10 handkerchiefs; Finally the drug-containing dish lid of powder charge is covered tightly, and load aluminium foil bag and carry out sealing and obtain loratadine compositions chewable tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410735868.6A CN104490819A (en) | 2014-12-05 | 2014-12-05 | Loratadine composition chewable tablets and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410735868.6A CN104490819A (en) | 2014-12-05 | 2014-12-05 | Loratadine composition chewable tablets and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104490819A true CN104490819A (en) | 2015-04-08 |
Family
ID=52932337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410735868.6A Pending CN104490819A (en) | 2014-12-05 | 2014-12-05 | Loratadine composition chewable tablets and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104490819A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018175261A1 (en) * | 2017-03-20 | 2018-09-27 | Bayer Healthcare Llc | Chewable gel products for active pharmaceutical ingredients |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1286629A (en) * | 1997-12-29 | 2001-03-07 | 宝洁公司 | Tablet composition |
| CN1568992A (en) * | 2004-04-24 | 2005-01-26 | 深圳海王药业有限公司 | Orally disintegrating tablet of loratadine and its preparation method |
-
2014
- 2014-12-05 CN CN201410735868.6A patent/CN104490819A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1286629A (en) * | 1997-12-29 | 2001-03-07 | 宝洁公司 | Tablet composition |
| CN1568992A (en) * | 2004-04-24 | 2005-01-26 | 深圳海王药业有限公司 | Orally disintegrating tablet of loratadine and its preparation method |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018175261A1 (en) * | 2017-03-20 | 2018-09-27 | Bayer Healthcare Llc | Chewable gel products for active pharmaceutical ingredients |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104490925A (en) | Vitamin D calcium composition chewable tablets and preparation method thereof | |
| CN104490814A (en) | Zinc gluconate composition chewable tablets and preparation method thereof | |
| CN104434972A (en) | Calcium hydrophosphate composite chewable tablet and preparation method thereof | |
| CN104490819A (en) | Loratadine composition chewable tablets and preparation method thereof | |
| CN102772383A (en) | Azithromycin composition freeze-dried orally disintegrating tablet and preparation method thereof | |
| CN104490924A (en) | Sucralfate composition chewable tablets and preparation method thereof | |
| CN102525978A (en) | Children amoxicillin-potassium clavulanate composition | |
| CN104490813A (en) | Dextromethorphan hydrobromide composition chewable tablets and preparation method thereof | |
| CN104490807A (en) | Ambroxol hydrochloride composition chewable tablet and preparation method thereof | |
| CN104490811A (en) | Aspirin composition chewable tablet and preparation method thereof | |
| CN104523613A (en) | Montelukast sodium composition chewable tablet and preparation method thereof | |
| CN104490805A (en) | Simvastatin composition chewable tablets and preparation method thereof | |
| CN104490820A (en) | Gentamicin sulfate composition chewable tablets and preparation method thereof | |
| CN104490926A (en) | Calcium carbonate composition chewable tablet and preparation method thereof | |
| CN104490816A (en) | Chewable tablet prepared from ferrous fumarate composition and preparation method thereof | |
| CN104490804A (en) | Cimetidine composition chewable tablets and preparation method thereof | |
| CN104434834A (en) | Mebendazole composition chewable tablet and preparation method thereof | |
| CN104490806A (en) | Vitamin C composition chewable tablets and preparation method thereof | |
| CN104490818A (en) | Famotidine composition chewable tablet and preparation method thereof | |
| CN104434830A (en) | Erythromycin ethylsuccinate chewable tablet and preparation method thereof | |
| CN104490808A (en) | Cefixime composition chewable tablets and preparation method thereof | |
| CN102525979B (en) | Infant ibuprofen composition | |
| CN104490815A (en) | Chewable tablet prepared from bismuth potassium citrate composition and preparation method thereof | |
| CN104473890A (en) | Fenofibrate composition chewable tablet and preparation method thereof | |
| CN104523612A (en) | Calcium lactate composition chewable tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150408 |